CGEN
Closed
Compugen
1.73
-0.05 (-2.81%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.78
Day's Range: 1.7 - 1.795
Send
sign up or login to leave a comment!
When Written:
0.702
Compugen is a computational drug discovery company that uses artificial intelligence (AI) and machine learning (ML) to develop new therapies for various diseases. The company was founded in 1993 and is headquartered in Israel.
Compugen's technology platform, called Predictive Discovery, is designed to identify novel drug targets and develop therapeutic antibodies and small molecule drugs. The platform uses advanced algorithms and data analysis techniques to predict the function of genes and proteins, and to identify potential drug candidates.
The company's pipeline includes several drug candidates in various stages of development, including treatments for cancer, autoimmune diseases, and infectious diseases. Compugen has partnerships with several pharmaceutical companies, including Bristol Myers Squibb, AstraZeneca, and Bayer.
Compugen is also active in the field of biomarker discovery, with a focus on developing diagnostic tests for cancer and other diseases. The company's biomarker discovery platform, called Biomarker Generator, uses AI and ML to analyze large amounts of genomic and proteomic data to identify potential biomarkers.
Overall, Compugen is a leading player in the field of computational drug discovery, with a strong focus on using AI and ML to accelerate the development of new therapies for unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Compugen's technology platform, called Predictive Discovery, is designed to identify novel drug targets and develop therapeutic antibodies and small molecule drugs. The platform uses advanced algorithms and data analysis techniques to predict the function of genes and proteins, and to identify potential drug candidates.
The company's pipeline includes several drug candidates in various stages of development, including treatments for cancer, autoimmune diseases, and infectious diseases. Compugen has partnerships with several pharmaceutical companies, including Bristol Myers Squibb, AstraZeneca, and Bayer.
Compugen is also active in the field of biomarker discovery, with a focus on developing diagnostic tests for cancer and other diseases. The company's biomarker discovery platform, called Biomarker Generator, uses AI and ML to analyze large amounts of genomic and proteomic data to identify potential biomarkers.
Overall, Compugen is a leading player in the field of computational drug discovery, with a strong focus on using AI and ML to accelerate the development of new therapies for unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!